LABT
First patient, first real test
Lakewood-Amedex Biotherapeutics just crossed a big milestone: it dosed the first patient in its Phase 2a trial for Nu-3, a topical antimicrobial gel aimed at mildly infected diabetic foot ulcers. That’s biotech-speak for “now the molecule has to prove it can actually do something useful in humans,” which is usually where the story gets interesting — or awkward.
What the trial is trying to prove
The study is testing three Nu-3 strengths — 2%, 5%, and 10% — in adults with Type 1 or Type 2 diabetes. The company says researchers will look at:
- safety
- therapeutic efficacy
- microbial burden reduction
- resolution of active infection
That matters because diabetic foot ulcers are the kind of problem nobody wants, but a lot of patients need better options for. If Nu-3 can clear microbes without running into the usual antibiotic-resistance headache, that’s the kind of angle investors perk up for.
Why Wall Street will care
This trial is more than a box-check. The results will help Lakewood-Amedex choose a dose for future studies, and the company already plans to follow this with a Phase 2b trial comparing once-daily and twice-daily dosing against placebo. Topline data are expected in the first quarter of 2027, which means this one’s going to simmer for a while.
Shares were down 3.93% at $1.81 when the story landed, and with the stock hovering near its 52-week low, the market is clearly not handing out bonus points for optimism alone.
Big picture: In biotech, “first patient dosed” is the moment the science stops being PowerPoint and starts being real.